Research ArticleClinical Investigations
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, Lucia Nogova, Adriaan A. Lammertsma, Ronald Boellaard, Bernd Neumaier, Roland T. Ullrich, Arne Holstein, Markus Dietlein, Jürgen Wolf and Carsten Kobe
Journal of Nuclear Medicine December 2011, 52 (12) 1871-1877; DOI: https://doi.org/10.2967/jnumed.111.094458
Deniz Kahraman
Matthias Scheffler
Thomas Zander
Lucia Nogova
Adriaan A. Lammertsma
Ronald Boellaard
Bernd Neumaier
Roland T. Ullrich
Arne Holstein
Markus Dietlein
Jürgen Wolf
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 52, Issue 12
December 1, 2011
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, Lucia Nogova, Adriaan A. Lammertsma, Ronald Boellaard, Bernd Neumaier, Roland T. Ullrich, Arne Holstein, Markus Dietlein, Jürgen Wolf, Carsten Kobe
Journal of Nuclear Medicine Dec 2011, 52 (12) 1871-1877; DOI: 10.2967/jnumed.111.094458
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, Lucia Nogova, Adriaan A. Lammertsma, Ronald Boellaard, Bernd Neumaier, Roland T. Ullrich, Arne Holstein, Markus Dietlein, Jürgen Wolf, Carsten Kobe
Journal of Nuclear Medicine Dec 2011, 52 (12) 1871-1877; DOI: 10.2967/jnumed.111.094458
Jump to section
Related Articles
Cited By...
- Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors
- Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma
- Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab